Skip to content 
Starpax Biopharma
In the high-stakes world of oncology, where innovation can mean the difference between life and loss, few companies dare to challenge the fundamentals of how cancer is treated. Starpax Biopharma Inc. is one such pioneer—reimagining drug delivery through a bold fusion of biology, physics, and artificial intelligence.
At the center of this transformative vision is Michael Gareau, President, CEO, and Chairman, whose decades-long entrepreneurial journey has culminated in a mission deeply rooted in both scientific ambition and personal purpose.
A Vision Fueled by Science—and Something More Personal
With over 40 years of experience spanning engineering, finance, and innovation, Gareau brings a rare blend of technical expertise and strategic leadership. Before founding Starpax, he led Ipax Capital, where he evaluated thousands of cutting-edge technologies and investment opportunities across global markets.
But in 2016, two patents changed everything.
The discovery—centered on Virtual Monopole Magnetic Field Vectors—represented years of research involving nearly 200 scientists. For Gareau, it wasn’t just another investment opportunity. It was a breakthrough with the potential to redefine cancer treatment.
Motivated by the memory of his father, who passed away from cancer, Gareau made a life-altering decision: he left behind his established ventures, relocated to Canada, and committed himself fully to bringing this technology to life.
The Core Problem: Why Cancer Treatments Often Fall Short
Despite decades of progress in oncology, a critical challenge persists—drug delivery inside tumors.
Studies show that up to 90% of a tumor may receive little to no therapeutic drug, largely due to:
- Collapsed or abnormal blood vessels
- Poor lymphatic circulation
- Dense tumor structures that block diffusion
Even the most advanced therapies struggle to penetrate the entire tumor mass effectively.
The Breakthrough: Magnetodrones and Precision Delivery
Starpax Biopharma’s solution is as unconventional as it is groundbreaking.
The company has developed living “Magnetodrones”—engineered bacteria capable of carrying anticancer drugs and navigating through tumor tissues. These microscopic agents are guided using controlled magnetic fields, enabling targeted and uniform drug distribution.
At the center of this system is PolarTrak, a proprietary medical device that allows precise 3D control of these Magnetodrones within the tumor.
How It Works:
- Magnetodrones are injected directly into the tumor
- Magnetic fields guide them through the tumor’s internal structure
- Drugs are delivered evenly across the entire tumor volume
- The system minimizes exposure to healthy tissues
The result? A radically improved delivery mechanism that bypasses the limitations of traditional chemotherapy.
Promising Early Results
Preclinical studies conducted by independent laboratories have shown remarkable outcomes:
- 100% remission rates in controlled models
- No significant side effects observed
- Up to 50x higher drug concentration within tumors
- 800x reduction in toxic exposure to the rest of the body
While these findings are still under rigorous validation, they represent a potential paradigm shift in how cancer could be treated in the future.
Built on Credibility, Not Hype
In an industry where breakthroughs often face skepticism, Starpax has taken an uncompromising stance on transparency and scientific rigor.
To ensure credibility:
- Preclinical trials are conducted and verified by independent GLP-certified laboratories
- Clinical trials are overseen by multiple Contract Research Organizations (CROs)
- Additional independent firms supervise the auditing process
This multi-layered validation approach reflects the company’s commitment to exceeding regulatory and ethical standards.
Beyond Cancer: A Platform for Broader Impact
While oncology remains the primary focus, Starpax’s technology has far-reaching potential.
Its platform is being explored for conditions where drug delivery is equally challenging, including:
- Ischemic heart disease
- Pulmonary hypertension
- Stroke
- Diabetic retinopathy
By enabling targeted therapy in hard-to-reach areas of the body, Magnetodrones could unlock new treatment possibilities across multiple medical fields.
Looking Ahead: Clinical Trials and Global Impact
Starpax is preparing for the next critical phase—clinical trials using advanced adaptive Bayesian protocols. The company aims to move toward regulatory approvals and eventual commercialization within a structured timeline.
With solid tumors accounting for nearly 90% of all cancer cases globally, the potential market—and impact—is immense.
Equally important is accessibility. By leveraging drugs with expired or near-expiry patents, Starpax aims to deliver cost-effective treatments, making advanced care more widely available.
Leadership Spotlight: Michael Gareau
Michael Gareau’s journey is one of resilience, conviction, and vision. From leading global investment ventures to pioneering a new frontier in cancer treatment, his career reflects a consistent pursuit of meaningful innovation.
At Starpax, that vision is clear:
to transform cancer treatment from systemic and imprecise to targeted, efficient, and patient-centered.
A Future Rewritten
Starpax Biopharma is not just developing a new treatment—it is redefining how medicine approaches one of humanity’s most persistent challenges.
By merging microbiology, electromagnetism, and artificial intelligence, the company is opening doors to a future where cancer treatment is:
- More precise
- Less toxic
- More effective
- More accessible
In a field where incremental progress is the norm, Starpax is aiming for something far greater—a complete shift in the rules of engagement.
